NEW YORK (GenomeWeb News) – GeneNews said today that under a new agreement drugmaker Eli Lilly will have select access to its osteoarthritis genomic biomarker program.
Toronto-based GeneNews specializes in using functional genomics for biomarker-based early disease diagnosis.
GeneNews Lead Director and Interim CEO Heiner Dreismann said in statement that the firm's Sentinel Principle technology "can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program."
Financial terms of the agreement were not released.